Our Team
*The NanoDx™ System has not been evaluated by the FDA or other regulatory agencies.
Design and development by Raincastle Communications.
Executive Chairman
Mr. Wylie is a proven business leader with more than 45 years of executive management experience in emerging and global businesses. He has held leadership positions as a general manager, division president, group executive and chief executive officer in both public and private sector companies including IMC, Albany International, Uniroyal, EcoScience, and Diomed Holdings. Additionally, Mr. Wylie spent 9-years as a turnaround specialist in the venture capital field.
(Full Corporate and Executive management background available upon request.)
President & CEO
George Serafin is a 35+ year seasoned professional possessing a unique blend of industry, technology, and management consulting experience spanning R&D, engineering, supply chain, manufacturing, quality, regulatory, compliance, corporate/operations, and information technology across medical device and diagnostics, pharmaceuticals, biotechnology, and consumer healthcare. He earned a B.Eng degree in Biomedical Engineering with a double minor in Electrical Engineering and Biophysics and an M.Sc. in Technology Management from the Stevens Institute of Technology.
CCO
Mike Sampson is an accomplished global commercial leader with a successful 26-year track record in business development, strategic sales & commercial marketing management within the medical device and diagnostics point-of-care IVD industry. Mike has led teams across the globe establishing strategic partnerships to drive success within sales, marketing, and information technology. Leveraging his background in lab and point-of-care diagnostics, Mike has launched numerous GTM plans into new markets and rebuilt approaches to traditional markets to drive success into the future. Across the last 12 years, Mike has focused his passion on POC as a true solution that improves the interaction and outcomes with the patient, while also delivering the ability to reduce the overall costs of healthcare.
VP Operations
Rajeeva Lahri is a seasoned Executive with over 40 years of experience in the Semiconductor Industry. He has a proven track record in building value that has led to several successful exits. Rajeeva has held Senior leadership positions in Supply Chain, Operations, R&D, and Business Management. He has worked for several Tier I companies like Global Foundries, Freescale Semiconductors, National Semiconductors, VLSI Technology/ NXP, Intersil, and Hewlett Packard.
Founder, EVP, CTO
Mr. McGlynn is the founder and Chief Technical Officer of NanoDx, Inc. He has been a part of the medical device industry for over 30 years. He began his career in cardiovascular products working with Bentley to produce tubing packs and oxygenators for open-heart procedures and working to build the team of investigators for the St Jude prosthetic heart valve. Mr. McGlynn has consulted with clients from several industries helping them to recognize the needs of the marketplace and succeed in a global market.
Director of Assay Development
Dr. Lisa-Jo Clarizia is a seasoned scientific director, with nearly thirty years of experience in immunoassay development, with a focus on IVD assay development. Throughout her career, she has developed immunoassays and cell-based assays for several biotechnology and medical device companies. Dr. Clarizia received her doctorate in Biochemistry from the University of Massachusetts, Lowell and has authored several scientific papers and has been awarded multiple patents.
Associate Director of Sensor Development
Dr. Farhad Khosravi is a seasoned professional with over a decade of experience in the field of next generation diagnostic technology, where he has made significant contributions to advancing point-of-care solutions. His critical role at NanoDx over the past six years has led to numerous patents and has driven major technological shifts, including the successful collaboration with industry giants like IBM and MIT. Beyond his technical expertise, Dr. Khosravi is recognized for his strategic vision and ability to lead teams towards innovative solutions. He holds advanced degrees in Bioengineering from the University of Louisville and a Ph.D. in Mechanical Engineering from Worcester Polytechnic Institute, with a specialization that bridges biosensors and nanotechnology.
Senior Director of Finance
Robert Pratt serves as the Senior Director of Finance. Robert has 25 years of experience as a financial leader in the life science and consumer product industries. He has directed several financing initiatives, and has led several M&A,’s licensing transactions, and strategic partnerships. Mr. Pratt has an established track record building scalable finance teams to support rapid growth and commercial success. Before joining NanoDx, Mr. Pratt served as Corporate Controller for Frequency Therapeutics, Inc., a biotechnology company focused on the development of regenerative treatments for Hearing Loss and Multiple Sclerosis, where he developed the finance function for the newly public company to support its clinical development efforts. Prior to Frequency Therapeutics, he served as Controller for Curis, Inc., a biotechnology company focused on the development of oncology treatments. Prior to Curis, Mr. Pratt spent several years in roles of increasing responsibility in accounting and finance functions at several Fortune 500 companies in both the life science and consumer product industries. He earned a B.S. in Business from Virginia Commonwealth University, an MBA from Boston University, and is a Certified Public Accountant.
Director of Human Resources
Jennifer joined NanoDx, Inc. in 2022, bringing 25 years of performance-driven expertise from both the medical device and manufacturing industries. Her background encompasses workforce development, benefits management, payroll and employment compliance, with a strong emphasis on employee relations and wellness promotion.
Having previously developed a Human Resources department from scratch into a two-time winner of Providence Business Journal’s Healthiest Employers, she enjoys building on that experience to enhance the employee experience at NanoDx.
Executive Chairman
Mr. Wylie is a proven business leader with more than 45 years of executive management experience in emerging and global businesses. He has held leadership positions as a general manager, division president, group executive and chief executive officer in both public and private sector companies including IMC, Albany International, Uniroyal, EcoScience, and Diomed Holdings. Additionally, Mr. Wylie spent 9-years as a turnaround specialist in the venture capital field.
(Full Corporate and Executive management background available upon request.)
President & CEO
George Serafin is a 35+ year seasoned professional possessing a unique blend of industry, technology, and management consulting experience spanning R&D, engineering, supply chain, manufacturing, quality, regulatory, compliance, corporate/operations, and information technology across medical device and diagnostics, pharmaceuticals, biotechnology, and consumer healthcare. He earned a B.Eng degree in Biomedical Engineering with a double minor in Electrical Engineering and Biophysics and an M.Sc. in Technology Management from the Stevens Institute of Technology.
Founder, CTO
Mr. McGlynn is the founder and Chief Technical Officer of NanoDx, Inc. He has been a part of the medical device industry for over 30 years. He began his career in cardiovascular products working with Bentley to produce tubing packs and oxygenators for open-heart procedures and working to build the team of investigators for the St Jude prosthetic heart valve. Mr. McGlynn has consulted with clients from several industries helping them to recognize the needs of the marketplace and succeed in a global market.
(Full Corporate and Executive management background available upon request.)
Board Member
Mr. Brackett has 34 years of experience in the financial services industry primarily focused on private equity and venture capital investing, fund development and operational management, investment banking, and structured finance. Mr. Brackett is President, Managing Member and Co-Head of Alternative Investments, and a member of the Management and Investment Committees at Shepherd Kaplan Krochuk, LLC, a $9 Billion investment management & advisory firm headquartered in Boston, MA.
(Full Corporate and Executive management background available upon request.)
Board Member
With over 30 years of global leadership in the medical device industry, Dr. Boulnois has developed early-stage companies, participated in an Initial Public Offering, and led several M&As, licensing transactions, and financing rounds. His strong operational experience in multiple medical specialties (cardiovascular, neurosurgery, etc.) and deep relationships throughout industry, enabled him to focus on managing high growth opportunities, through innovation, unique business models, international expansion, or strategic acquisitions.
(Full Corporate and Executive management background available upon request.)
Board Member
Mr. Lockhart is an owner and a member of the Management Board of Shepherd Kaplan Krochuk. He is the founder, Chief Executive Officer and Chief Investment Officer of Peak Capital Management, LLC (PCM), which SKK acquired in February 2020. With over 25 years of portfolio management experience, he serves as the co-portfolio manager of PCM’s suite of proprietary strategies, directing the company’s dynamic allocation of distinguished ETF investment strategies implemented on behalf of high net worth, institutional clients.
(Full Corporate and Executive management background available upon request.)
Board Member
Mr. Perlstein brings more than 45 years of experience as a legal practitioner, law firm and business leader, and experienced advisor to our Board. Mr. Perlstein is currently Senior Managing Director and Vice-Chair, Client Services, at FTI Consulting, which he joined in late 2019. Mr. Perlstein previously served as Senior Deputy General Counsel at BNY Mellon where he was responsible for the legal teams supporting the bank’s regulatory, government relations and corporate services functions.
(Full Corporate and Executive management background available upon request.)
Scientific & Strategic Advisor
Dr. John Kelly has nearly four decades of experience innovating and leading in the Information Technology industry. Throughout his distinguished career, he has held significant technical and business roles driving IBM’s leadership in technologies ranging from semiconductors to supercomputers to artificial intelligence cognitive systems. A champion of IBM’s technical community, he has steered IBM’s leadership in U.S. patents for the last 27 years.
Chief Medical Advisor
Dr. Zafonte is the President of Spaulding Rehabilitation Network and the Earle P. and Ida S. Charlton Professor and Chairman of the Harvard Medical School Department of Physical Medicine and Rehabilitation (PM&R). He also serves as Chief of PM&R Massachusetts General Hospital, Chair of the Department of PM&R at Brigham and Women’s Hospital, and Senior Vice President of Medical Affairs, Research and Education at Spaulding Rehabilitation Network.
Scientific Advisor
Dr. Kevin Reagan is virologist/immunologist and a consultant on the assay development component of the NanoDx™ platform. Over a 40-year career, Kevin has led product development and operational activities at multiple international biotechnology and medical device companies. Kevin considers his expertise to be the integration of life science tools (recombinant proteins, monoclonal antibodies and immunoassays) with various engineering platforms to create a unique offering with tactical advantages over competition. Kevin has supported company’s strategy with over 12 acquisitions or mergers where he did technical evaluations, integration and served as a board member on companies prior to acquisition.
Executive Director Home Base (A Red Sox Foundation and Massachusetts General Hospital Program)
Leads the nation’s premier center of excellence for the mental health and brain injuries that affect our Veterans and their families. Drawing upon the faculty of Massachusetts General Hospital, Harvard Medical School, and the Spaulding Rehabilitation Hospital, Home Base has reimagined what is possible by developing new treatment models and a full spectrum of care for the invisible wounds of war. General Hammond has raised more than 130 million dollars to fund breakthrough clinical programs at the nation’s first and largest private sector clinical center for Veterans. This state-of-the-art national center for innovation has delivered first class care and support, at no cost, to more than 25,000 people from all 50 states and 6 countries. In addition, the Home Base faculty has trained more than 75,000 clinicians, participated in national research projects, and most recently launched a national media channel to extend the reach of its non-clinical programs.
Last served as the 12th commander of the United States Special Operations Command from March 29, 2019, to August 30, 2022. Prior to assuming command of USSOCOM, General Clarke served as Director for Strategic Plans and Policy, Joint Staff, the Pentagon, Arlington, Virginia. General Clarke’s other assignments as a general officer include: Deputy Commanding General for Operations, 10th Mountain Division from 2011-2013; the 74th Commandant of Cadets, United States Military Academy at West Point from 2013-2014; and the Commander of the 82nd Airborne Division from 2014-2016. General Clarke’s deployments while serving in the aforementioned positions include Operations Desert Shield and Desert Storm, Operation Joint Guardian in Macedonia, three deployments in support of Operation Enduring Freedom, four deployments in support of Operation Iraqi Freedom, and one deployment as the commander of the Combined Joint Forces Land Component Command. He is a graduate of West Point. He was commissioned into the Infantry Branch in 1984.
Previous served as deputy commander of United States Special Operations Command from October 15, 2018, to December 2021. He is the former commander of United States Naval Special Warfare Command in Coronado, California. Admiral Syzmanski’s Naval Special Warfare (NSW) and operational assignments include platoon commander and task unit commander at SEAL Delivery Vehicle Team 2 and as a troop commander, squadron commander and operations officer and as operations officer and deputy commanding officer at the Naval Special Warfare Development Group. He was commanding officer of Special Boat Unit 26 and later returned to NSWDG for a 2nd tour as unit operations officer for 2000 to 2002. Admiral Szymanski’s staff assignments include officer community manager for NSW and enlisted community manager for SEALs, Navy Divers, explosive ordinance disposal (EOD) technicians, and special warfare combatant craft crewmen (SWCC). He served on the Joint Staff as the J3 deputy directorate for Special Operations as the Global War on Terror branch chief and as chief staff officer of Pakistan-Afghanistan Coordination Cell. In past assignments, Admiral Syzmanski served as assistant commanding officer to Joint Operations Command prior to assuming command of naval Special Warfare Command.
Independent consultant. Works with people and organizations to bring innovative solutions to national security problems. Executive Advisor to the Emory Healthcare Veterans Program in Atlanta, GA. Key member of the Warrior Care Network® treating post-traumatic stress disorder, traumatic brain injury, trauma, anxiety, and depression related to military service. Culminating military assignment with Deputy Commander of United States European Command where he provided leadership to address complex security challenges across 51 nations, including 28 NATO nations. Previously served as Deputy Commanding General of U.S. Army Forces Command, responsible for the readiness of approximately 800,000 Active Army, U.S. Army Reserve, and Army National Guard soldiers – majority of the Army’s combat power.
Executive leader in healthcare traumatic brain injury, strategy, leadership, and policy. Neurologist, Nuclear Medicine, and Molecular Imaging physician. Served as the Brain Health Research Program Coordinator for the DoD Blast Injury Research Program Coordinating Office and as the Medical Advisor to the Assistant for Research and Technology (PAR&T), Medical Research and Material Command, FT Detrick, MD. Served as national director of Defense and Veterans Brain Injury Center Co-Principal Investigator, Long-term impact of Military-relevant Brain Injury Consortium-Chronic Effects of Neurotrauma Consortium. While deployed to Afghanistan oversaw care at 11 concussion care centers. Dr. Hinds was the National Director of the Defense and Veterans Brain injury Center (DVBIC), which supported treatment sites and clinical research, educated service members and caregivers, and consolidated and reported data on TBI. Currently, Assistant Professor, Departments of Radiology and Neurology, Uniformed Services University, United States Military Academy, BS Engineering. Earned is Medical Degree from University of Connecticut Health Center.
Currently 10th Command Senior Enlisted Leader, U.S. Special Operations Command (USSOCOM), MacDill AFB, Florida. He assumed the position on July 11, 2019. USSOCOM is one of the 11 combatant commands within the Department of Defense unified command structure. Chief Smith entered The U.S. Air Force in 1990 as an aircraft armament systems specialist. His initial assignment was with the 3246th Test Wing, Eglin AFB, Florida. In 1993, Chief Smith was reassigned to the 355th Fighter Squadron, Eielson AFB, Alaska where he served as a weapons load crew member on A/OA-10 aircraft. He completed multiple deployments to the Pacific Theater and was part of the first team to deploy following the terror attach on 9/11. In January 2012, Chief Smith was selected from Command Master Sergeant for the 58th Special Operations Wing where he oversaw the training and readiness for special operations and combat rescue personnel. In 2013 he was selected as the Command Sr. Enlisted Leader for SOC Europe in 2013 where he led special operations forces through multiple contingencies in Ukraine, Turkey, and Syria. In 2015 he became the Command Senior Enlisted Leader for NATO Special Operations Headquarters. His last assignment was as a Command Senior Enlisted Leader for USSOC. Throughout his career, Chief Smith completed 14 combat deployments, flew more than 3,500 hours including 1,400 combat hours.